Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2008, Vol. 35 Issue (2): 130-132    DOI:
Original Research Previous articles | Next articles
Misoprostol use as a method of medical abortion
N. Salakos1, C. Iavazzo1, *(), K. Bakalianou1, O. Gregoriou1, G. Paltoglou1, K. Kalmantis1, D. Botsis1
12nd Department of Obstetrics and Gynecology, University of Athens, Aretaieion Hospital, Athens (Greece)
Download:  PDF(56KB)  ( 9 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Aim: The aim of our study was to verify with the use of ultrasound (US) scanning the effectiveness of misoprostol in medical abortion. Materials and Methods: The study population included women with a medical miscarriage attending the 2nd Department of Obstetrics and Gynecology, University of Athens in Aretaieion Hospital, Athens, Greece. All women < 49 days since their last menstruation received 800 μg vaginal misoprostol. The diagnosis of complete abortion was possible by the US measurements as endometrial thickness of 15 mm by transvaginal US was used as a cutoff level for successful abortion. Results: The mean age of the study population was 27 years (ranging from 19 up to 37 years). Complete evacuation with misoprostol was performed in 149 women. The success rate was 85.2% (127/149). Twenty-two women experienced intrauterine echogenic structures with a diameter > 15 mm and all of them underwent surgical evacuation (14.8%). Vaginal bleeding was present in 17 patients after the procedure (11.4%). Less usual reported side-effects included nausea, vomiting, pain, or diarrhea. Conclusion: Misoprostol use is an effective, safe and acceptable method of medical abortion for women.
Key words:  Misoprostol      Miscarriage      Medical abortion      Transvaginal ultrasound     
Published:  10 June 2008     
*Corresponding Author(s):  C. IAVAZZO     E-mail:  christosiavazzo@hotmail.com

Cite this article: 

N. Salakos, C. Iavazzo, K. Bakalianou, O. Gregoriou, G. Paltoglou, K. Kalmantis, D. Botsis. Misoprostol use as a method of medical abortion. Clinical and Experimental Obstetrics & Gynecology, 2008, 35(2): 130-132.

URL: 

https://ceog.imrpress.com/EN/     OR     https://ceog.imrpress.com/EN/Y2008/V35/I2/130

[1] Wassan Nori, Muna Abdulghani, Ali B Roomi, Wisam Akram. To operate or to wait? Doppler indices as predictors for medical termination for first trimester missed abortion[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 168-174.
[2] N.K. Aref. Rectal misoprostol after cesarean delivery: does it affect recovery of bowel functions? A prospective randomized trial[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(6): 906-910.
[3] N. Al-Husban, A. Hababeh, M. Al-Kasasbeh, R. Odeh, M. Shaheen, D. Moughrabi, D. Zabalawi. Thyroid stimulating hormone (TSH) level variations in early pregnancy and feto-maternal outcome; retrospective study[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 675-680.
[4] A. A. Rouzi, R. Alamoudi, J. Turkistani, N. Almansouri, S. Alkafy, N. Alsinani, A. Wazzan. Miscarriage perceptions and experiences among Saudi women[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 208-214.
[5] S.Y. Jung, H.Y. Cho, S.H. Lee, S. Lim, K.B. Lee. Pregnancy outcomes of a giant primary ovarian leiomyoma in the first trimester[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(1): 135-138.
[6] R. Csorba, P. Tsikouras, A. Bothou, S. Zervoudis, G. Iatrakis, X. Anthoulaki, D. Deuteraiou, A. Chalkidou, G. F. von Tempelhoff. Air travel during pregnancy: an update review and practical recommendation[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(6): 862-866.
[7] E. Pereira Alves Filho, F.C. Nogueira Arcanjo, A.R. Mesquita Rocha, D. Frade Bernardes, M.H. Oliveira Santos, N.L. Pereira Coutinho. The efficacy and safety of intravaginal misoprostol for the induction of labor in patients with obstetrical or medical indication for labor induction[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(1): 81-84.
[8] J.H. Check. Pros and cons of the use of progesterone to reduce miscarriage rates[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 652-655.
[9] K. Chmaj-Wierzchowska, T. Olejniczak, J. Tuzel, J. Niepsuj-Biniaś, I. Kaczorowska, S. Husam, J. Budna, A. Dera-Szymanowska, K. Olejniczak, K. Szymanowski. Analysis of the cytokine profile (IL-2, IL-4, IL-6, IL-10, IL-17, IFN - γ and TNF-α) on threatened miscarriage[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 661-664.
[10] Hui-Dong Li, Zhi-Kun Zhang, Shuang Guo, Peng-Peng Qu. The application of contrast-enhanced ultrasound in the diagnosis of cesarean scar pregnancies[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 731-734.
[11] A.A. Rouzi, N. AlSinani, N. AlMansouri, N. Alsahly. Intra-cervical misoprostol for the treatment of second-trimester fetal demise[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(3): 344-346.
[12] T. Miyamoto, K. Abiko, A. Itabashi, G. Minase, H. Ueda, K. Sengoku. MD-TESE-ICSI using fresh sperm resulted in a lower rate of miscarriage compared with frozen-thawed sperm[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 229-230.
[13] I. Isidori, C. Spapperi, A. Barbati, A. Mencarelli, G. Stangoni. QF-PCR and MLPA: a reliable molecular system to detect chromosomal alterations in miscarriages[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(2): 220-225.
[14] F.Y. Azizieh, R. Raghupathy. IL-10 and pregnancy complications[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(2): 252-258.
[15] J.H. Check, D.L. Check. Intravenous intralipid therapy is not beneficial in having a live delivery in women aged 40-42 years with a previous history of miscarriage or failure to conceive despite embryo transfer undergoing in vitro fertilization-embryo transfer[J]. Clinical and Experimental Obstetrics & Gynecology, 2016, 43(1): 14-15.
No Suggested Reading articles found!